1. Home
  2. NAKA vs TLSA Comparison

NAKA vs TLSA Comparison

Compare NAKA & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kindly MD Inc.

NAKA

Kindly MD Inc.

N/A

Current Price

$9.44

Market Cap

152.1M

Sector

N/A

ML Signal

N/A

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

BUY

Current Price

$1.11

Market Cap

145.1M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
NAKA
TLSA
Founded
2019
2013
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
152.1M
145.1M
IPO Year
2023
2017

Fundamental Metrics

Financial Performance
Metric
NAKA
TLSA
Price
$9.44
$1.11
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
★ $13.33
$8.02
AVG Volume (30 Days)
202.6K
★ 597.6K
Earning Date
11-18-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 61.19
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
$3,833.87
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.15
$0.76
52 Week High
$10.53
$2.30

Technical Indicators

Market Signals
Indicator
NAKA
TLSA
Relative Strength Index (RSI) 57.87 54.76
Support Level $0.22 $0.90
Resistance Level $10.27 $1.20
Average True Range (ATR) 0.66 0.10
MACD -0.10 0.02
Stochastic Oscillator 54.25 68.02

Price Performance

Historical Comparison
NAKA
TLSA

About NAKA Kindly MD Inc.

Nakamoto Inc is a Bitcoin company building a world-wide portfolio of Bitcoin-native companies to provide commercial and financial infrastructure for the next generation of capital markets. The firm has two principal business segments: Bitcoin Operations, which houses its Bitcoin treasury and is utilized to support investments in other Bitcoin-related companies; Healthcare Operations, which provides a patient-focused healthcare experience that provides patients personalized solutions in order to reduce opioid use and improve health outcomes. The company generates the majority of its revenue from the Healthcare Operations.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

Share on Social Networks: